Dyadic Logo Current.jpg
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
10 nov. 2022 16h00 HE | Dyadic International, Inc.
Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for...
The Worldwide Monoclonal Antibodies in Veterinary Health Industry is Expected to Reach $2.6 Billion by 2030
08 nov. 2022 06h28 HE | Research and Markets
Dublin, Nov. 08, 2022 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies in Veterinary Health Market Share, Size, Trends, Industry Analysis Report, By Animal Type, By Application, By End-Use, By Region,...
Dyadic Logo Current.jpg
Dyadic to Present at Upcoming Industry and Investor Events in November
07 nov. 2022 08h30 HE | Dyadic International, Inc.
JUPITER, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
$264 Worldwide Monoclonal Antibody Therapeutics Industry to 2027 - Featuring AbbVie, Amgen, Bayer and Biogen Among Others
01 nov. 2022 05h28 HE | Research and Markets
Dublin, Nov. 01, 2022 (GLOBE NEWSWIRE) -- The "Global Monoclonal Antibody Therapeutics Market (2022-2027) by Source, End-Users, Applications, and Geography, Competitive Analysis and the Impact of...
Dyadic Logo Current.jpg
Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
27 oct. 2022 16h30 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
27 oct. 2022 09h04 HE | Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Global Research Antibodies Market Analysis Report 2022: A $2.21 Billion Market by 2030 - Expansion in Neurobiology and Stem Cell Research to Propel Growth
24 oct. 2022 04h23 HE | Research and Markets
Dublin, Oct. 24, 2022 (GLOBE NEWSWIRE) -- The "Research Antibodies Market Size, Share & Trends Analysis Report by Product (Primary, Secondary), by Type, by Technology, by Source, by Application,...
Cancer Monoclonal Antibodies Market Report 2022: Featuring AbbVie, Bristol-Myers Squibb, Eli Lilly, Pfizer, Novartis, Merck & More
19 oct. 2022 08h08 HE | Research and Markets
Dublin, Oct. 19, 2022 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibodies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Intravenous Immunoglobulin Global Market Report 2022: Growing Pharmaceutical Industry Presents Opportunities
12 oct. 2022 06h03 HE | Research and Markets
Dublin, Oct. 12, 2022 (GLOBE NEWSWIRE) -- The "Intravenous Immunoglobulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Application, Distribution Channel, End User, and...
logo 600X600.png
Global Immunohistochemistry Market to Surpass US$ 2,448.93 Million by 2030, Says Coherent Market Insights (CMI)
10 oct. 2022 09h10 HE | CMI
Seattle, Oct. 10, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global immunohistochemistry market is estimated to be valued at US$ 1,463.69 million in 2022 and expected to...